BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 32033280)

  • 1. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
    Sherman DJ; Li J
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32033280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation proteasome inhibitors for cancer therapy.
    Park JE; Miller Z; Jun Y; Lee W; Kim KB
    Transl Res; 2018 Aug; 198():1-16. PubMed ID: 29654740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
    Fogli S; Galimberti S; Gori V; Del Re M; Danesi R
    Pharmacol Res; 2021 May; 167():105537. PubMed ID: 33684510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Patatsos K; Shekhar TM; Hawkins CJ
    Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma--translation of trial results into reality.
    Moreau P; Rajkumar SV
    Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.